Plain-English translation of NCT06649240 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether people who've had a small vessel stroke—a specific type of stroke caused by tiny blood vessels—benefit more from aggressive cholesterol lowering or moderate cholesterol lowering. About 4,000 participants will be randomly assigned to take statins and other cholesterol-lowering medications targeting either very low cholesterol levels or moderate levels, then followed for at least 4 years to see which approach prevents more heart attacks and future strokes.
While doctors know that controlling cholesterol is important after a stroke, they don't yet have clear guidelines about exactly how low cholesterol should go for people with small vessel strokes specifically. This study aims to fill that gap so doctors can give you the most effective treatment plan tailored to your type of stroke.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: one targeting very low cholesterol (below 70 mg/dL) and one targeting moderate cholesterol (90–110 mg/dL). You'll take cholesterol-lowering medications as prescribed and visit the clinic regularly so doctors can check your cholesterol levels, adjust your medication if needed, and monitor your health. The study lasts at least 4 years, during which researchers will track whether you experience any heart attacks, strokes, or other serious cardiac events.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
South Korea